Literature DB >> 26693050

Breast cancer intrinsic subtype classification, clinical use and future trends.

Xiaofeng Dai1, Ting Li1, Zhonghu Bai1, Yankun Yang1, Xiuxia Liu1, Jinling Zhan1, Bozhi Shi2.   

Abstract

Breast cancer is composed of multiple subtypes with distinct morphologies and clinical implications. The advent of microarrays has led to a new paradigm in deciphering breast cancer heterogeneity, based on which the intrinsic subtyping system using prognostic multigene classifiers was developed. Subtypes identified using different gene panels, though overlap to a great extent, do not completely converge, and the avail of new information and perspectives has led to the emergence of novel subtypes, which complicate our understanding towards breast tumor heterogeneity. This review explores and summarizes the existing intrinsic subtypes, patient clinical features and management, commercial signature panels, as well as various information used for tumor classification. Two trends are pointed out in the end on breast cancer subtyping, i.e., either diverging to more refined groups or converging to the major subtypes. This review improves our understandings towards breast cancer intrinsic classification, current status on clinical application, and future trends.

Entities:  

Keywords:  Breast cancer; classification; clinical use; gene expression profiling; heterogeneity; intrinsic subtype; signature; trends

Year:  2015        PMID: 26693050      PMCID: PMC4656721     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  85 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  MYC-microRNA-9-metastasis connection in breast cancer.

Authors:  Maria Inês Almeida; Rui M Reis; George A Calin
Journal:  Cell Res       Date:  2010-05-25       Impact factor: 25.617

3.  A pathway-based classification of human breast cancer.

Authors:  Michael L Gatza; Joseph E Lucas; William T Barry; Jong Wook Kim; Quanli Wang; Matthew D Crawford; Michael B Datto; Michael Kelley; Bernard Mathey-Prevot; Anil Potti; Joseph R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-24       Impact factor: 11.205

Review 4.  Development and validation of gene expression profile signatures in early-stage breast cancer.

Authors:  Christine Desmedt; Christos Sotiriou; Martine J Piccart-Gebhart
Journal:  Cancer Invest       Date:  2009-01       Impact factor: 2.176

Review 5.  Molecular mechanisms of long noncoding RNAs.

Authors:  Kevin C Wang; Howard Y Chang
Journal:  Mol Cell       Date:  2011-09-16       Impact factor: 17.970

6.  Prevalence and correlates of HIV testing among sexually active African American adolescents in 4 US cities.

Authors:  Rebecca R Swenson; Christie J Rizzo; Larry K Brown; Nanetta Payne; Ralph J DiClemente; Laura F Salazar; Peter A Vanable; Michael P Carey; Robert F Valois; Daniel Romer; Michael Hennessy
Journal:  Sex Transm Dis       Date:  2009-09       Impact factor: 2.830

7.  Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival.

Authors:  Howard Y Chang; Dimitry S A Nuyten; Julie B Sneddon; Trevor Hastie; Robert Tibshirani; Therese Sørlie; Hongyue Dai; Yudong D He; Laura J van't Veer; Harry Bartelink; Matt van de Rijn; Patrick O Brown; Marc J van de Vijver
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-08       Impact factor: 11.205

Review 8.  Gene expression profiling in breast cancer: classification, prognostication, and prediction.

Authors:  Jorge S Reis-Filho; Lajos Pusztai
Journal:  Lancet       Date:  2011-11-19       Impact factor: 79.321

9.  Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland.

Authors:  A Spitale; P Mazzola; D Soldini; L Mazzucchelli; A Bordoni
Journal:  Ann Oncol       Date:  2008-12-12       Impact factor: 32.976

10.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Authors:  Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

View more
  288 in total

Review 1.  Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer.

Authors:  E Nilüfer Güler
Journal:  Eur J Breast Health       Date:  2017-10-01

Review 2.  Targeting forkhead box M1 transcription factor in breast cancer.

Authors:  Ruth M O'Regan; Rita Nahta
Journal:  Biochem Pharmacol       Date:  2018-05-31       Impact factor: 5.858

Review 3.  Racial disparity in breast cancer: can it be mattered for prognosis and therapy.

Authors:  Vijayalaxmi Gupta; Inamul Haque; Jinia Chakraborty; Stephanie Graff; Snigdha Banerjee; Sushanta K Banerjee
Journal:  J Cell Commun Signal       Date:  2017-11-29       Impact factor: 5.782

Review 4.  The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.

Authors:  Jordyn Kreutzfeldt; Brett Rozeboom; Nandini Dey; Pradip De
Journal:  Am J Cancer Res       Date:  2020-04-01       Impact factor: 6.166

5.  ZBTB7A governs estrogen receptor alpha expression in breast cancer.

Authors:  Mary Ellen Molloy; Monika Lewinska; Amanda K Williamson; Thanh Thao Nguyen; Gamze Kuser-Abali; Lu Gong; Jiawei Yan; John B Little; Pier Paolo Pandolfi; Zhi-Min Yuan
Journal:  J Mol Cell Biol       Date:  2018-08-01       Impact factor: 6.216

6.  A mouse model of chemotherapy-related cognitive impairments integrating the risk factors of aging and APOE4 genotype.

Authors:  Tamar C Demby; Olga Rodriguez; Camryn W McCarthy; Yi-Chien Lee; Christopher Albanese; Jeanne Mandelblatt; G William Rebeck
Journal:  Behav Brain Res       Date:  2020-02-03       Impact factor: 3.332

7.  Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance.

Authors:  Mingjun Bi; Zhao Zhang; Yi-Zhou Jiang; Pengya Xue; Hu Wang; Zhao Lai; Xiaoyong Fu; Carmine De Angelis; Yue Gong; Zhen Gao; Jianhua Ruan; Victor X Jin; Elisabetta Marangoni; Elodie Montaudon; Christopher K Glass; Wei Li; Tim Hui-Ming Huang; Zhi-Ming Shao; Rachel Schiff; Lizhen Chen; Zhijie Liu
Journal:  Nat Cell Biol       Date:  2020-05-18       Impact factor: 28.824

8.  The potential roles of lncRNAs DUXAP8, LINC00963, and FOXD2-AS1 in luminal breast cancer based on expression analysis and bioinformatic approaches.

Authors:  Maedeh Arabpour; Sepideh Mehrpour Layeghi; Javad Tavakkoly Bazzaz; Mohammad Mehdi Naghizadeh; Keivan Majidzadeh-A; Abbas Shakoori
Journal:  Hum Cell       Date:  2021-05-27       Impact factor: 4.174

9.  Splice variants of cytosolic polyadenylation element-binding protein 2 (CPEB2) differentially regulate pathways linked to cancer metastasis.

Authors:  James T DeLigio; Grace Lin; Charles E Chalfant; Margaret A Park
Journal:  J Biol Chem       Date:  2017-09-13       Impact factor: 5.157

10.  PTP1B promotes aggressiveness of breast cancer cells by regulating PTEN but not EMT.

Authors:  Xue Liu; Qian Chen; Xu-Gang Hu; Xian-Chao Zhang; Ti-Wei Fu; Qing Liu; Yan Liang; Xi-Long Zhao; Xia Zhang; Yi-Fang Ping; Xiu-Wu Bian
Journal:  Tumour Biol       Date:  2016-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.